NewsBite

Opthea Limited

ASX Announcements

Market Sensitive

Voluntary suspension

Suspension from Official Quotation

Market Sensitive

Trading Halt

Trading Halt

Becoming a substantial holder

Becoming a substantial holder

Application for quotation of securities - OPT

Appendix 2A (Application for Quotation of Securities)

Application for quotation of securities - OPT

Appendix 2A (Application for Quotation of Securities)

View all OPT announcements

This Month

Regal’s Phil King will be holding thumbs ahead of Opthea’s clinical trial results.

It’s Phil King’s Regal against the shorts at biotech play Opthea

The high-profile stockpicker is the eye disorder treatment hopeful’s biggest shareholder. Ahead of the results of a crucial clinical trial, shorts are rising.

June 2024

ASX-listed Opthea was in front of fund managers on Monday, seeking fresh funds.

Opthea launches $220 million capital raising, MST on ticket

The biotech has high hopes for a new drug that if successful could treat macular degeneration.

April 2024

It’s very difficult to pick biotech winners.

Why picking ASX biotechs is mostly for the crazy brave

It’s a space with a reputation for rollercoaster returns and outlandish sales pitches, but some investors get lucky.

October 2022

James McDonald is a portfolio manager at Pengana Capital Group.

The cash clues that suggest Dreamworld owner is wildly undervalued

Pengana’s James McDonald is tipping into Aussie names Telix and Opthea, potash producer K+S, and the valuation case for Ardent at 70¢.

August 2022

Opthea lead product OPT-302 should be fully funded to for the coming two years, the company told potential investors on Thursday.

Carlyle chases potential four-bagger at biotech Opthea

The Carlyle Group and its newly acquired life sciences arm Abingworth are chasing a four-bagger at Australian eye therapies developer Opthea.

Advertisement
Street Talk.

Eye therapies group Opthea in $US240m funding deal, chases equity leg

It’s a big day for ASX-listed Opthea, an eye therapies developer with a near $500 million market capitalisation. 

October 2020

ASX gains 1.2pc for week; Aussie Broadband soars 91pc

The Australian sharemarket notched up a second week of gains even as the S&P/ASX200 Index fell 0.5 per cent on Friday. Afterpay closed at a record high. Aussie Broadband surged on debut. Tyro gained 6 per cent on a deal with Bendigo Bank.

ASX gains; Six day winning streak as banks bounce; Link soars

The Australian sharemarket notched up a sixth straight days of gains as banks rallied off their session lows. Carlyle and Pacific Equity Partners offered $5.20 a share for Link. Aware Super raised its bid for OptiComm to $6.50 a share. Bravura bought UK-based Delta for $41.5 million.

September 2020

Banks rally lifts stocks to best week since mid-August

The sharemarket advanced 1.7 per cent over the week as banks enjoyed a massive rally on Friday. Westpac's 7 per cent surge helped steer the S&P/ASX200 Index 1.5 per cent higher on Friday as the government moved to relax responsible lending rules.

June 2020

Australian Ethical's Andy Gracey likes biotechs with multiple programs, that have advanced out of the petri dish.

Momentum builds for small cap biotechs

Australian Ethical's Andy Gracey likes companies that have real signs of efficacy and are no longer in the petri dish.

November 2019

CSL rose over 3 per cent following an upgrade to 'buy' by UBS.

Healthcare stocks tipped for strong 2020 as clinical trial results pour in

Investors have returned to the big life sciences companies as growth in other sectors has slowed, says Morgans.

September 2019

Paul Rennie's Paradigm Biopharmaceuticals is developing a treatment for osteoarthritis that helps with pain management, but also stops the disease progressing.

Small cap healthcare stocks surge to billion-dollar plays

Successful results from a handful of emerging biotech companies have shifted investor sentiment about the sector.

Original URL: https://www.afr.com/company/opt-152